Maintenance therapy: Oral azacitidine in patients with AML improves long-term overall survival
The phase-III trial QUAZAR AML-001 investigates the effects of treatment with oral azacitidine as maintenance therapy on long-term overall survival (OS) in patients with acute myeloid leukemia. After an additional year of follow up, Professor Andrew Wei presents the updated results on OS as well as additional characteristics of the long-term survivors. The results indicate that maintenance therapy provides a sustained benefit on long-term OS.
If you are a doctor, nurse, or other health professionals, you can access the entire article by creating a profile on BestPractice Nordic.